Roche licenses Zymeworks' trispecific T cell engager ZW209 in up-to-$813M lung cancer deal
Start here
Roche has paid Zymeworks $55 million upfront for an exclusive global license to ZW209, a trispecific T cell engager it plans to develop for lung cancer. The deal could reach $813 million in total. A further $40 million is due if ZW209 enters Phase 1b testing, and Zymeworks is eligible for up to $718 million in development, commercial and sales milestones, plus high-single-digit to mid-teen royalties on future net sales. The partnership was announced on October 23, 2026; no clinical results for ZW209 under Roche have been reported yet.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- biospace.comPickRoche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
Roche is paying a $55 million upfront for an exclusive global license to Zymeworks' ZW209 and plans to develop it for lung cancer, in a deal worth up to $813 million. If ZW209 enters Phase 1b testing, Roche will pay an additional $40 million, plus up to $718 million in development, commercial and sales milestones. Zymeworks is eligible for high-single-digit to mid-teen royalties on future net sales.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 23 20:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.